TICKER INTELLIGENCE
NYSE/NASDAQ: DHR
Danaher is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 2 active Congressional signals mentioning Danaher, including 2 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
Danaher ($DHR) is currently facing 2 active congressional signals tracked by HillSignal. With 0 bullish, 1 neutral, and 1 bearish signals, the average legislative impact score is 2.5/10. Key sectors affected include Healthcare and Technology. Recent major catalysts include Protecting Life and Integrity in Research Act of 2025 and Preventing Illegal Laboratories and Protecting Public Health Act of 2026. Below is the complete tracker of government activity affecting Danaher’s market performance.
2
Total Signals
2.5/10
Avg Impact
0
Bullish Signals
1
Bearish Signals
S.4227 mandates logbook requirements for distributors of highly pathogenic agents but authorizes no funding and remains in early legislative stages. The bill creates incremental compliance costs without altering demand, resulting in neutral-to-modestly-negative near-term impact. Pure-play distributor AVTR faces disproportionate relative burden versus diversified TMO and DHR.
HR2075 is an early-stage House bill that would ban federal funding for research using human fetal tissue from induced abortions. It is stuck in committee with no floor action since introduction in March 2025. The market data shows a broad 30-day decline across biomedical stocks, but $TMO and $DHR have moved -1.19% and +0.72% respectively in the past 7 days — not signaling acute legislative risk. The bill has zero direct appropriations and remains a low-probability risk factor for life sciences tool suppliers.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →